Fundraising FoxHexamer Therapeutics
Pullman, US · Founded 2019 · Delaware corporation
Find your way into Hexamer Therapeutics
Each arrow is one introduction. Sign up to fill in the first one.
Ask Avinash Kant to introduce you to Collin Collins
You →Avinash · together at Lawrence Berkeley National Laboratory →Collin
Sign up to find every way you can get introduced to Hexamer Therapeutics
- Your email: who you already know at Hexamer Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Hexamer Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Hexamer Therapeutics develops a modular, room-temperature, peptide-based vaccine platform for therapeutic cancer and infectious disease vaccines, aiming to move quickly from disease target to active vaccine. It also licenses the platform to companies developing vaccines for animals such as swine, cattle, sheep, horses and companion animals.
Founders & leadership
Board
Reported raises · per SEC filings
Form D private placements$1.6M disclosed across 3 rounds · 2019–2026
▶$500KraisedSep 2026 · 2 investors · BiotechnologyRule 506(b)
- Robert H BogdenExecutive Officer, Director
- Colin CollinsDirector
- Keith MillerDirector
- R. Scott BlackleyDirector
- Stephen CrawfordDirector
- Brad CallDirector
- Offering amount
- $2.5M
- Amount sold
- $500K
- First sale
- Jul 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$651.3KraisedJun 2024 · 9 investors · BiotechnologyRule 506(b)
- ROBERT H BOGDENExecutive Officer, Director, Promoter
- KEITH MILLERDirector
- R. SCOTT BLACKLEYDirector
- COLIN COLLINSDirector
- STEPHEN CRAWFORDDirector
- Offering amount
- $6.6M
- Amount sold
- $651.3K
- First sale
- Jan 2024
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$469.7KraisedDec 2019 · 3 investors · BiotechnologyRule 506(b)
- Keith David MillerExecutive Officer, Director, Promoter
- Robert Hale BogdenExecutive Officer, Director, Promoter
- Colin Conrad CollinsExecutive Officer, Director, Promoter
- Offering amount
- $1.1M
- Amount sold
- $469.7K
- Proceeds to insiders
- $1M
- First sale
- Nov 2019
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Hexamer Therapeutics do?
- Hexamer Therapeutics develops a modular, room-temperature, peptide-based vaccine platform for therapeutic cancer and infectious disease vaccines, aiming to move quickly from disease target to active vaccine. It also licenses the platform to companies developing vaccines for animals such as swine, cattle, sheep, horses and companion animals.
- How much funding has Hexamer Therapeutics raised?
- Hexamer Therapeutics has disclosed $1.6M raised across 3 rounds.
- Where is Hexamer Therapeutics headquartered?
- Hexamer Therapeutics is headquartered in Pullman, US.